requirements after transplant in pediatric heart recipients J Heart Lung Transplant 2011;30(12):1352–1359 109 Lalan S, Abdel-Rahman S, Gaedigk A, et al Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population Pediatr Nephrol 2014 110 de Wildt SN, van Schaik RH, Soldin OP, et al The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation Eur J Clin Pharmacol 2011;67(12):1231–1241 111 Kausman JY, Patel B, Marks SD Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients Pediatr Transplant 2008;12(3):329–335 112 Birdwell KA, Decker B, Barbarino JM, et al Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing Clin Pharmacol Ther 2015;98(1):19–24 113 Davies RO, Gomez HJ, Irvin JD, Walker JF An overview of the clinical pharmacology of enalapril Br J Clin Pharmacol 1984;18(suppl 2):215S–229S 114 Liu L, Cui Y, Chung AY, et al Vectorial transport of enalapril by Oatp1a1/MRP2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers J Pharmacol Exp Ther 2006;318(1):395–402 115 Tian L, Liu H, Xie S, et al Effect of organic anion-transporting polypeptide 1b1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men Clin Ther 2011;33(5):655–663 116 Yang D, Pearce RE, Wang X, et al Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin Biochem Pharmacol 2009;77(2):238–247 117 Boberg M, Vrana M, Mehrotra A, et al Agedependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LCMS/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants Drug Metab Dispos 2016 118 Johnson TN The problems in scaling adult drug doses to children Arch Dis Child 2008;93(3):207–211 119 Kauffman RE Clinical trials in children: problems and pitfalls Paediatr Drugs 2000;2(6):411–418 120 Johnson TN, Rostami-Hodjegan A Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice Paediatr Anaesth 2011;21(3):291–301 121 Edginton AN, Schmitt W, Willmann S Development and evaluation of a generic physiologically based pharmacokinetic model for children Clin Pharmacokinet 2006;45(10):1013–1034 122 Abdel-Rahman SM, Breitkreutz ML, Bi C, et al Design and testing of an EHR-integrated, Busulfan pharmacokinetic decision support tool for the Point-of-care clinician Front Pharmacol 2016;7:65 123 Best Pharmacueticals for Children Act Pub L No 107-109 124 Pediatric Research Equity Act of 2003 Pub L No 108-155 125 Frattarelli DA, Galinkin JL, Green TP, et al Offlabel use of drugs in children Pediatrics 2014;133(3):563–567 126 Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD Pediatric information in drug product labeling JAMA 2012;307(18):1914– 1915 ... Best Pharmacueticals for Children Act Pub L No 107-109 124 Pediatric Research Equity Act of 2003 Pub L No 108-155 125 Frattarelli DA, Galinkin JL, Green TP, et al Offlabel use of drugs in children Pediatrics 2014;133(3):563–567... Johnson TN, Rostami-Hodjegan A Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased... Offlabel use of drugs in children Pediatrics 2014;133(3):563–567 126 Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD Pediatric information in drug product labeling JAMA 2012;307(18):1914– 1915